GH - Guardant Health, Inc.
| Previous Close | 41.89 |
| Open | 41.73 |
| Bid | 39.50 x 1100 |
| Ask | 41.80 x 1000 |
| Day's Range | 38.02 - 41.85 |
| 52 Week Range | 27.04 - 49.55 |
| Volume | 778,020 |
| Avg. Volume | 800,512 |
| Market Cap | 3.414B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Motley Fool•13 days ago
The Probable Reason Guardant Health Is Soaring Today
This recent IPO is red hot, but what can explain today's jump?
- American City Business Journals•20 days ago
Here's how much better insiders have profited from this year's IPO boom
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
- MarketWatch•27 days ago
Guardant Health reports first earnings since IPO
Guardant Health Inc. reported earnings late Monday that missed Wall Street profit expectations but beat on sales. It was the company's first earnings since its initial public offering earlier this year. Guardant reported third-quarter net losses of $24.5 million, or $1.94 a share, compared with losses of $33.3 million, or $2.76 a share, in the year-ago period. Revenue rose to $21.7 million from $11.1 million in the year-ago period. The five analysts surveyed by FactSet had estimated losses of 29 cents a share on revenue of $17.4 million. For the fourth quarter, analysts model losses of 32 cents a share on sales of $21.2 million. Guardant said it expects full-year 2018 revenue of $82 million to $84 million; the FactSet consensus is for revenue of $74.4 million. Guardant stock closed down roughly 10% in Monday trading, with the S&P 500 index falling 1.7%.
- Yahoo Finance•last month
Where SoftBank’s Vision Fund is deploying its $100 billion
SoftBank's Vision Fund portfolio includes a little of everything, from startups that send satellites to space, to one that helps humans walk dogs. Here's what it means for the market.
- American City Business Journals•2 months ago
Strong IPO pace continued in October but some cracks are showing
Nearly half of the 22 U.S. IPOs in October priced below their range, according to Renaissance Capital, which manages exchange-traded funds made up of IPO stocks. Several more were postponed.
American City Business Journals•2 months agoHealth Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
Small VistaGen is building a portfolio of drugs aimed at depression and other mental health conditions, while giant Gilead gets a lower effective tax rate — all that and more in our Health Care Digest.
- American City Business Journals•2 months ago
Unicorn births outpace IPOs in Bay Area: Here are the 24 new ones so far this year
Only eight of the Bay Area's unicorns have gone public this year. Meanwhile, 24 new ones have been born. Here's a look at all of them.
- MarketWatch•2 months ago
Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early
The startup’s cancer tests help match patients with the right treatments. It also has even bigger ambitions: to use its tests to find cancer recurrences, and even for early detection of cancers.
- MarketWatch•2 months ago
Guardant Health's stock soars in public debut after IPO prices above expectations
Shares of Guardant Health Inc. soared in their public debut Thursday, as they opened 46% above the initial public offering price, which was well above the expected range. The first trade for the cancer detection and treatment company's stock was at $27.75 at 10:48 a.m. ET for 1.7 million shares. That compares with the IPO price of $19, which was above the expected range of $15 to $17. The stock has extended gains since then, to trade up 51%. The company raised $237.5 million with the IPO, which values the company at $1.6 billion. Guardant is going public at a time that the Renaissance IPO ETF has slipped 0.9% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 7.5% and the S&P 500 has advanced 7.1%.
- MarketWatch•2 months ago
Guardant Health IPO prices above expected range to value company at $1.6 billion
Guardant Health Inc. said Thursday its initial public offering of 12.5 million shares priced at $19 a share, above the expected range of $15 to $17 a share, to raise $237.5 million. If the underwriters exercise all the options granted to buy additional shares, oncology company could raise up to $273.1 million. The IPO pricing values the Redwood City, Calif.-based company at $1.59 billion. The company had a net loss of $83.2 million on revenue of $49.8 million in 2017, compared with a loss of $46.1 million and revenue of $25.2 million in 2016. The stock is expected to begin trading Thursday on the Nasdaq under the ticker symbol "GH." The company is going public at a time that the Renaissance IPO ETF has gained 5.0% year to date and the S&P 500 has gained 9.4%.
- Benzinga•3 months ago
IPO Outlook For The Week: Diagnostics, Data Miners And Freelance Facilitators
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Upwork Inc. (UPWK) will issue nearly 12.3 million shares between $10 and $12 Wednesday on the Nasdaq. Upwork’s online platform ...
